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doi:10.1016/j.jtcvs.2007.04.060bjective: Surgical resection is the standard of care for stage I non–small cell lung
ancer. The objective of this study was to evaluate computed tomography–guided
adiofrequency ablation as an alternative treatment option for high-risk patients with
tage I non–small lung cancer.
ethods: Patients with medically inoperable stage I non–small lung cancer were
ffered radiofrequency ablation. Thoracic surgeons evaluated and performed radio-
requency ablation under computed tomographic scanning guidance. Response was
ssessed by means of computed tomographic and positron emission tomographic
canning. Time to progression and survival were monitored every 3 months.
esults: Nineteen patients underwent radiofrequency ablation over a 3-year period.
here were 8 men and 11 women with a median age of 78 years (range, 68-88
ears). Radiofrequency ablation resulted in pneumothorax requiring a pigtail cath-
ter in 12 (63%) patients. An initial complete response was observed in 2 (10.5%)
atients, a partial response in 10 (53%) patients, and stable disease in 5 (26%)
atients. Early progression occurred in 2 (10.5%) patients. During follow-up, local
rogression occurred in 8 (42%) nodules, and the median time to progression was
7 months. There were no procedure-related mortalities, and 6 deaths occurred
uring follow-up. The mean follow-up in the remaining patients was 29 months
range, 9-52 months). The probability of survival at 1 year was estimated to be 95%
95% confidence interval, 0.85-1.0). The median survival was not reached.
onclusion: Our experience indicates that radiofrequency ablation is safe in high-
isk patients with stage I non–small lung cancer, with reasonable results in patients
ho are not fit for surgical intervention.
ung cancer is the most common cause of cancer-related mortality in the
United States. Surgical resection is the standard treatment in resectable
disease and offers the best chance of cure, particularly in the earlier stages.1-3
n an aging population, many patients with otherwise resectable lung cancer have
ther comorbidities, including pulmonary dysfunction, which might preclude them
rom surgical resection.4 In these patients conventional external beam radiotherapy
s typically offered as treatment, with reported 5-year survival rates of 10% to
0%.5-8 Sibley and colleagues6 reviewed the results of radiotherapy for stage I
on–small lung cancer (NSCLC) from Duke University in 156 patients and reported
2- and 5-year survival of 39% and 13%, respectively. Recently, Qiao and
ssociates8 reviewed 18 studies investigating the treatment of stage I NSCLC with
adiotherapy and reported a mean 3-year and 5-year overall survival of 34% and
1%, respectively. Thus the results of conventional radiotherapy have not been
atisfactory, prompting investigators to study other modalities of treatment, such as
adiofrequency ablation (RFA), in this high-risk group of patients with lung cancer.
The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 4 857
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G
TSThe use of interstitial hyperthermia to treat lung neo-
lasm was initially reported by Lilly and colleagues9 in
983. RFA is a thermal ablative technique and is a relatively
ew modality of treatment, which might be applicable in
igh-risk patients with lung cancer. There have been several
eports in the literature on the use of RFA for lung neo-
lasm, but many of these are case reports or series with a
ocus on immediate response, without rigorous longer-term
ollow-up for recurrence or survival.10-14 Furthermore, there
re few reports with an emphasis on stage I NSCLC. We
ave previously described our experience with RFA in the
reatment of both primary and metastatic lung neo-
lasms.15,16 The principal findings of our earlier report
ere that RFA was more effective for smaller (5 cm)
umors, with better early survival and response to treatment.
dditionally, in our previous report, we described a modi-
cation of the Response Evaluation Criteria in Solid Tu-
ors (RECIST) criteria (Table 1) that were used to assess
reatment response and progression at the ablated sites. In
his article we report our experience with the use of RFA in
he treatment of stage I NSCLC in medically inoperable
atients. This is part of an ongoing institutional review
oard-approved study that continues to accrue at the
niversity of Pittsburgh.
Abbreviations and Acronyms
CCI  Charlson Comorbidity Index
CT  computed tomography
FEV1  forced expiratory volume in 1 second
NSCLC  non–small cell lung cancer
PET  positron emission tomography
RECIST Response Evaluation Criteria in Solid Tumors
RFA  radiofrequency ablation
SRS  stereotactic radiosurgery
ABLE 1. Modified RECIST criteria
esponse CT scan mass size
omplete (2 of the following) Lesion disappearance (sca
or 25% original size
artial (1 of the following) 30% Decrease in the sum
LD of target lesions
table lesion (1 of the
following)
30% Decrease in the sum
LD of target lesions
rogression (2 of the
following)
Increase of 20% in sum
LD of target lesions
T, Computed tomography; PET, positron emission tomography; SUV, stand
D, lesion diameter. *Positron emission tomographic scan done selectively.
58 The Journal of Thoracic and Cardiovascular Surgery ● Octoaterials and Methods
e reviewed our experience with RFA for the treatment of stage I
on–small lung neoplasm in medically inoperable patients at the
niversity of Pittsburgh over a 3-year period from 2002-2005. Some
f these patients have been reported previously.16 Informed consent
as obtained from all patients, and the study was approved by the
nstitutional Review Board at the University of Pittsburgh.
election of Patients
atients with NSCLC were routinely staged with chest computed
omographic (CT) scanning, and most patients also underwent a
ositron emission tomographic (PET) scan. Patients with medias-
inal lymph nodes greater than 1 cm in the short axis, a positive
ET scan result, or both underwent mediastinoscopy. Mediasti-
oscopy was performed in 2 patients, and left-sided video-assisted
horacoscopic surgery was performed in 1 patient for biopsy of
ilar and aortopulmonary window nodes. The inclusion criteria for
FA in the treatment of patients with stage I NSCLC for this study
ere as follows: (1) patients who were considered medically
noperable because of poor pulmonary function, high cardiac risk,
nd/or other comorbidities and (2) presence of a target tumor of 4
m or smaller. In addition, patients who refused an operation were
ffered RFA if the tumor was peripheral and less than 4 cm.
xclusion criteria included central tumors. All patients were eval-
ated by a thoracic surgeon to determine inoperability and suit-
bility for RFA.
reatment Protocol
Technique. A percutaneous CT-guided approach was used in
ll patients, and as described previously, all procedures were
erformed by thoracic surgeons.15,16 The RFA equipment consists
f a generator, active electrode, and dispersive pads. Electrosur-
ical dispersive pads (Dispersive Electrodes, RITA Medical Sys-
ems, Inc, Moutainview, Calif, or Valleylab Polyhesive, Valleylab,
oulder, Colo) were applied to the patient’s thighs and plugged
nto the return electrode socket on the front panel of the radiofre-
uency generator.
RFA was performed by using 2 different radiofrequency gen-
rators and needle electrodes. The radiofrequency generator was
et up in accordance with the generator’s instructions for use. One
CT scan mass quality PET scan*
Cyst cavity formation;
low density
SUV  2.5
Mass central necrosis
or central cavity with
liquid density
Decreased SUV or area
of FDG uptake
Mass solid appearance,
no central necrosis
or cavity
Unchanged SUV or
area of FDG uptake
Solid mass, invasion
adjacent structures
Higher SUV or larger
area of FDG uptake
ed uptake value of fluorodeoxyglucose F18; FDG, fluorodeoxyglucose F18;r)
ardizber 2007
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G
TSystem comprised of a radiofrequency generator (RF3000; Boston
cientific Corp, Boston, Mass) and needle electrodes (LeVeen
eedle Electrode; RadioTherapeutics Corporation, Sunnyvale,
alif). Under CT guidance, a finder needle (22-gauge long
pinal needle) was used to determine the trajectory and place-
ent of the active RFA probe. The LeVeen needle electrode
Boston Scientific Corp), which opens up as an array, was
elected according to the diameter of the target lesion and
laced into the target lesion. A 2-phase impedance-based algo-
ithm was used according to the protocol suggested by the
anufacturer. Briefly, the initial power applied was at the
owest setting and then increased in 5- to 10-W increments until
ystem impedance increased to more than 400 . A second
pplication of radiofrequency energy (a second phase) was
rovided at this same location (after waiting approximately 30
econds) until system impedance increases to more than 400 
or a second time.
The second system was comprised of a radiofrequency gener-
tor, the RITA Starburst XL Electrosurgical Device (RITA Med-
cal Systems, Inc). Based on the size of the target tumor, the
ultitined expandable array (Starburst XL Electrosurgical Device,
ITA Medical Systems, Inc) was deployed. Temperature was
onitored from 5 electrodes, which are equipped with thermocou-
les. The radiofrequency generator was set to a target temperature
f 90°C, and the initial power was applied at between 35 and 50
. The electrosurgical needle’s deployment was staged according
o the size of the tumor being treated, and the manufacturer-
uggested algorithm was followed.
With both of these systems, if necessary, the electrode was
epositioned as many times as necessary to encompass the
arget tissue and a small rim with approximately 0.5 to 1 cm of
ondiseased pulmonary tissue to ensure an adequate tumor
argin.
Postprocedure follow-up of patients and assessment of re-
ponse. Patients were followed up in 3-month intervals with clin-
cal examinations, CT scans, and selectively with PET scans.
odified RECIST criteria were used to assess initial response to
reatment at 3 to 5 months (Table 1).13,14 Patients were evaluated
or initial response rate, time to local progression, and overall
urvival.
ata Collection and Statistical Analysis
he objective of the study was to determine the outcomes of RFA
n the treatment of stage I NSCLC. Information on patient demo-
raphics, tumor characteristics, treatment, and comorbidities
Charlson Comorbidity Index [CCI]) were collected.17 Specific
nd points studied were complications, clinical response rates,
ime to local progression, and overall survival. The pretreatment
T scan was used as a baseline for evaluation of response and
isease progression. Local disease progression of the treated nod-
le was assessed in accordance with the modified RECIST criteria
n comparison with baseline diameter. The time to progression was
alculated from the treatment date. Kaplan–Meier plots were con-
tructed by using Greenwood confidence limits. The log–rank test
as used to determine differences between groups. Association
etween categoric variables was tested with the Fisher exact test or
he 2 test. m
The Journal of Thoracicesults
ineteen patients underwent RFA over a 3-year period.
here were 8 men and 11 women with a median age of 78
ears (range, 68-88 years). There were 11 patients with
tage IA and 8 with stage IB NSCLC. The mean size of the
esion was 2.6 cm (range, 1.6–3.8 cm). These patients had
ignificant comorbidities with the CCI, mean score being
.5 (range, 3-12; median, 4). The most common reason for
FA was poor pulmonary function test results precluding
esection. The median forced expiratory volume in 1 second
FEV1) in these patients was 0.66 (29% of predicted value),
ith a mean FEV1 of 0.73  0.21. Patient characteristics
nd other reasons for RFA are summarized in Table 2.
The median hospital stay was 3 days (range, 1–7 days).
he most common complication was pneumothorax requir-
ng a pigtail catheter in 12 (63%) patients. Prolonged air
eak (5 days) occurred in 1 (5%) patient. There were no
rocedure-related mortalities. Initial response was deter-
ined by using the modified RECIST criteria (Table 1). An
nitial complete response was observed in 2 (10.5%) pa-
ients. A partial response was observed in 10 (53%) patients.
n these patients size criteria were met in 5 patients, and in
he remaining 5 patients, a combination of decrease in
etabolic activity on PET scanning, cavitation in the lesion,
r both was used to determine partial response. All 3 criteria
ere met in 1 patient, 2 criteria were met in 5 patients, and
criterion (size [n  2], cavitation [n  1]; low metabolic
ctivity, standardized uptake value  0.6 on PET scan
n  1]) was met in 4 patients. Stable disease was noted in
(26%) patients. Early progression (at the time of assess-
ABLE 2. Patient characteristics
Sex (male/female) 8/11
Median age (y) 78 (range, 68–88)
Stage
IA 11
IB 8
Staging procedures
CT scan 19
PET scan 15
Mediastinoscopy/VATS 2
Histology
Squamous 8
Adenocarcinoma 8
Other 3
Reason for RFA*
Poor PFT results 10
Increased cardiac risk 7
Multiple comorbidities 8
T, Computed tomography; PET, positron emission tomography; VATS,
ideo-assisted thoracoscopic surgery; RFA, radiofrequency ablation; PFT,
ulmonary function test. *Some patients had more than 1 reason for
adiofrequency ablation.ent of initial response) occurred in 2 (10.5%) patients.
and Cardiovascular Surgery ● Volume 134, Number 4 859
6
n
t
f
2
s
(
fi
v
u
n
L
m
w
(
s
s
t
s
D
S
a
t
f
a
t
v
m
m
o
i
n
u
S
r
t
a
r
w
o
F
R
i
b
p
i
t
e
l
p
c
I
w
f
o
r
t
y
a
m
p
t
i
r
t
r
p
s
d
p
a
e
s
1
R
w
m
1
v
r
F
e
i
a
General Thoracic Surgery Pennathur et al
8
G
TSThere were no procedure-related mortalities. There were
deaths during follow-up; 3 were cancer related, and 2 were
ot cancer related. One patient had distant recurrence, and
he exact cause of death was not determined. The mean
ollow-up in the remaining patients was 29 months (median,
8 months; range, 9–52 months). The probability of overall
urvival at 1 year and 2 years were estimated to be 95%
95% confidence interval, 85%-100%) and 68% (95% con-
dence interval 49%–96%), respectively. The median sur-
ival was not reached (Figure 1).
During follow-up, local progression, as determined by
sing the modified RECIST criteria, occurred in 8 (42%)
odules, and the median time to progression was 27 months.
ocal progression was confirmed in 3 (16%) patients by
eans of biopsy. Patients with locally progressive disease
ere treated with repeat RFA or stereotactic radiosurgery
SRS)/external beam radiation. One patient underwent re-
ection. Patients with distant recurrences were treated with
ystemic therapy. No significant differences were noted in
he time to progression and survival when patients with
tage IA and IB disease were compared.
iscussion
urgical intervention is the treatment of choice for resect-
ble lung cancer and offers the best chance for cure.1-3 In
he medically inoperable patients with lung cancer, there are
ew effective options. Some of these patients with other
ssociated comorbidities refuse treatment or receive no
reatment with poor results. McGarry and coworkers18 re-
iewed the outcomes in 49 patients who received no treat-
ent in early-stage disease, and the median survival was 14
onths. Progressive cancer was the cause of death in 53%
igure 1. Kaplan–Meier plot showing the overall survival for the
ntire group with confidence limits. The time shown in the x-axis
s in months from radiofrequency ablation (RFA). The dotted lines
re 95% confidence bands for the probability of overall survival.f patients. Conventional radiotherapy, as described earlier, w
60 The Journal of Thoracic and Cardiovascular Surgery ● Octos offered to many of these patients, and the results again are
ot encouraging.5-8 Therefore in this high-risk patient pop-
lation with lung cancer, newer modalities, such as RFA or
RS, might be applicable.19-21 Timmerman and associates20
eported the results in 37 patients with stage I NSCLC
reated with SRS. The disease-free and overall survivals at
median follow-up of 15 months were 50% and 64%,
espectively. We have presented our early results in patients
ith stage I NSCLC treated with SRS with a 91% one-year
verall survival at a median follow-up of 15 months.21
urther prospective studies are required to define the role of
FA and SRS in the treatment of lung neoplasms.
The issue of determination of medical operability or
noperability is critically important and should be assessed
y a thoracic surgeon. One factor alone, such as poor
ulmonary function test results, might not make a patient
noperable. With the potential benefits of lung volume reduc-
ion surgery, selected patients with upper lobe–predominant
mphysema who have a coexistent lung cancer in the upper
obe may be candidates for lung resection, even when the
ulmonary function test results are marginal. Choong and
olleagues22 reported a series of 21 patients with clinical stage
NSCLC with a mean FEV1 of 0.7 (29% of predicted value)
ho underwent surgical resection. Lobectomy alone was per-
ormed in 9 patients, and in the remaining patients lobectomy
r sublobar resection was supplemented with lung volume
eduction surgery. In patients with pathologic stage I disease,
he overall survival was 100%, 79%, and 68% at 1, 3, and 5
ears, respectively. Therefore the assessment of medical oper-
bility requires a comprehensive evaluation of not only pul-
onary function but also other factors and comorbidities in the
atient by a qualified thoracic surgeon.
We have previously reported the results of RFA in the
reatment of both primary and metastatic lung cancer in
noperable high-risk patients.15,16 There have been very few
eports of patients with stage I NSCLC who have been
reated with RFA. Lee and associates11 reported their expe-
ience in 10 patients with stage I NSCLC. Of these 10
atients, only 4 were considered high-risk patients in whom
urgical intervention was contraindicated, and the remain-
er refused surgical intervention. Mean survival in these 10
atients was reported to be 21 months, and 80% were alive
t a mean follow-up of 14.8 months. Lencioni and cowork-
rs23 presented their preliminary results in 14 patients with
tage I disease. Kaplan–Meier analysis showed an overall
-year survival of 81% at a mean follow-up of 9 months.
ecently, Dupuy and colleagues24 reported their experience
ith RFA followed by external beam radiation in the treat-
ent of stage I NSCLC. At a mean follow-up of 26 months,
4 (58%) patients had died, and the estimated overall sur-
ival was 83% and 50% at 1 and 2 years, respectively. Our
esults of 95% overall survival in 1 year compare favorably
ith the results of these studies.
ber 2007
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G
TSThese results during intermediate-term follow-up are en-
ouraging, and the results appear to be equivalent or superior to
he reported results with conventional radiation therapy.5-8
owever, longer follow-up for this cohort is required, and full
valuation of survival end points will require greater maturity
f time-to-event data. In addition, further prospective studies
re required in high-risk patients to definitively compare
FA with conventional external beam radiation treatment or
ther emerging technologies, such as SRS.
This group of patients had significant associated comor-
idities, with a mean Charlson score of 5.5 and a median
CI of 4. The CCI was originally described to assess the
ffect of comorbidity on survival in 559 hospitalized pa-
ients. Nineteen conditions were found to significantly in-
uence survival in the study population, and a weighted
core was given based on the relative risk.17 This score has
een validated in surgically resected patients with NSCLC
n a study of 205 patients.25 The score was divided into 4
rades of increasing severity of the CCI index, with greater
han 5 representing the highest grade of comorbidities.
ultivariate analysis showed that a CCI 3 to 4 was the only
redictive factor of increased risk of major complications
odds ratio, 9.8; 95% confidence interval, 2.1-45.9), and for
very increase in grade, the relative risk of an adverse
utcome showed an increase. In the current study patients
ho underwent RFA were elderly (median age, 78 years),
ad significant comorbidities (mean CCI, 5.5), and repre-
ent a high-risk population.
The assessment of response after RFA is difficult be-
ause, unlike surgical resection, there is a lesion or scar that
emains after therapy. There is considerable variation in
ow response is defined and evaluated. Chest CT scans,
hanges in contrast enhancement, and PET scans have all
een used. Thus the reported response rate in the literature
aries considerably. We have adopted strict criteria and
ave used modified RECIST criteria to evaluate response in
hese patients after RFA. We have combined not only the
ize of the lesion but also the changes in the density of the
esion along with metabolic activity based on PET scans
o determine the response rate. The proposed modified
ECIST criteria have limitations and have to be validated in
larger group of patients. Ultimately, however, disease
rogression and survival will be the measures by which the
fficacy of RFA will have to be evaluated.
There are several factors that influence local recurrence
r progression of disease. The important technical issues
nclude (1) the degree of ablation and whether complete
blation is achieved and (2) the adequacy of margins of
blation obtained around the tumor. Completeness of abla-
ion has also been evaluated in a few ablate-and-resect
tudies examining the extent of ablation after RFA. Review
f these studies shows that effective 100% ablation varies
rom 38% to 67%. Yang and coworkers26 presented the g
The Journal of Thoracicesults of a multicenter ablate-and-resect study in 13 pa-
ients. The median tumor kill was 70%, and 7 (55%) pa-
ients had 100% ablation. These investigators also demon-
trated a learning curve that exists in achieving 100%
blation. Nguyen and associates27 did a prospective ablate-
nd-resect study after open thoracotomy in patients with
tage I or II NSCLC. RFA of the tumor was performed after
standard thoracotomy, and subsequently, a lobectomy was
erformed. Tumor cell viability was determined by means
f routine histology, as well as supravital dye staining.
hree (38%) of 8 patients had complete ablation of tumors.
n another study by Ambrogi and colleagues,28 a total of 9
atients underwent RFA either by means of the CT-guided
pproach or by means of open thoracotomy followed by
esection.28 Complete ablation was noted in 6 (67%) of 9
atients. However, supravital dye was not used to determine
ell viability. The margins of ablation were a mean of 8 mm
n completely ablated lesions and less than 5 mm in patients
ho had an incomplete ablation.
The adequacy of margins of ablation obtained around the
umor might be an important factor in local progression of
isease. Our data with regard to wedge resections suggest a
ignificant increase in the local recurrence rates (14.6% vs
.5%) when the margins were less than 1 cm versus more
han 1 cm.29 In general, we strive to attain a 0.5- to 1-cm
argin around the tumor. Despite these margins, local pro-
ression (as determined by imaging studies) occurred in
2% of patients, and the median time to progression was 27
onths. However, despite this incidence of progression, the
esults in terms of overall survival appear reasonable at
ntermediate-term follow-up. It is possible that the early
etection of recurrence by means of close follow-up and the
rompt treatment of recurrence might have contributed to
he results of overall survival, but the limited number of
atients did not allow us to derive definitive conclusions. In
he future, further advances in technology or adjuvant ther-
py might be useful in decreasing this progression rate and
erhaps in improving survival.
onclusions
n summary, this study is a preliminary report on the use of
FA for the treatment of stage I NSCLC in medically
noperable patients. The results with regard to overall sur-
ival seem reasonable, with an estimated 1-year overall
urvival rate of 95%. There are, however, several factors
hat merit further investigation, including optimal patient
election for RFA and the role of adjuvant therapy. Surgical
esection is the standard treatment for stage I NSCLC in
perable patients1-3; however, RFA might have a role in
atients who are medically inoperable. Prospective studies
re necessary to address these issues and to define the role
f RFA in the treatment of lung neoplasms. Thoracic sur-
eons should continue to evaluate new technology and add
and Cardiovascular Surgery ● Volume 134, Number 4 861
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TShese techniques to their armamentarium in the treatment of
ung neoplasms. In conclusion, RFA appears safe in high-
isk patients with stage I NSCLC, with reasonable results in
atients who are not fit for surgical intervention.
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r Donald E. Low (Seattle, Wash). Dr Millien, Dr Sintek, mem-
ers, and guests, thank you very much. I appreciate the opportunity
f discussing this article. I also would like to thank the authors for
etting me the manuscript immediately before the meeting for
eview.
This article describes RFA treatment of 19 patients with stage
disease. All patients were reviewed by thoracic surgeons and
ere deemed inoperable on medical grounds. The authors should
e congratulated in that surgeons not only carried out the assess-
ent of these patients but also delivered the actual RFA therapy in
he operating room. This is the third publication from your group
xamining RFA therapy in different patient populations. Your first
tudy in 2003 examined 18 patients, 5 of whom had NSCLC. The
ext report in 2005 reported 18 patients, all of whom had NSCLC,
ut 50% had stage I disease. Clearly you are beyond the point of
tudying the feasibility of RFA in lung cancer and at a point where
he focus should be on results, development of criteria for appli-
ation of RFA, and, just as importantly, redefinition of criteria for
edical inoperability. With that in mind, I believe that in a study
f patients with true stage I disease, we should be very careful
bout opening the door to any nonsurgical approach, except in very
arefully documented circumstances. Lung volume reduction sur-
ery has taught us that pulmonary function tests are not the
bsolute limiting factor about who can undergo surgical interven-
ion. Fifteen of 19 patients in your series were considered inoper-
ble on the basis of “poor pulmonary function test results.” How-
ver, the only objective indication you documented in your article
as mean and median FEV1. Although it is reassuring that all of
our patients were reviewed by thoracic surgeons, your current
eport would seem to provide excessive leeway for nonsurgeons to
esignate patient as nonsurgical candidates.
Do you not believe that at a minimum you should provide more
pecifics regarding predictable FEV and diffusion capacity in1
dentifying persons who are inoperable on the basis of pulmonary
ber 2007
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TSunction test results? In addition, should your conclusions not
nclude a strong statement that short of being in a clinical trial,
atients with stage I disease should always be seen by experienced
horacic surgeons and be presented in a multidisciplinary tumor
oard before being relegated to RFA therapy?
Dr Pennathur. Those are all valid points, and I think that one
f the main issues regarding RFA is that there is not enough
ollow-up evaluating long-term results in the literature. In a recent
eview of the literature, most studies were case series with very
oor follow-up and minimal information on how the recurrence
as determined and the nature of the long-term results. That is one
f the reasons why we wanted to and continue to study this more
igorously.
In terms of pulmonary function tests, our protocol comprises
asically a predicted postoperative FEV1 value of less than 40% as
ne of the criteria. We use several criteria, with a complete
ssessment of the patient. Pulmonary function test results alone are
ot the sole criterion. The median FEV1 of these patients was 0.6,
nd these were elderly patients (median age, 78 years) who had
ultiple comorbidities. One of the measures of comorbidity that
e assessed was the Charlson Comorbidity Score, which takes into
onsideration literally 19 conditions. It has been validated in
everal cancers and now has also been validated in lung cancer. In
ne study, in which the index was divided into categories of 0, 1
o 2, 3 to 4, and the worst at greater than 5, an index of greater than
to 4 was shown to be significantly associated with an increase in
ostoperative complications. The mean Charlson Comorbidity
core in our group of patients as a whole was greater than 5. I
hare your concern that if these patients are not evaluated by
horacic surgeons and instead evaluated by others making the
ecision on inoperability, that is not right for the patient. As you
ointed out, with the benefits of lung volume reduction surgery,
hese patients have to be evaluated by a thoracic surgeon, regard-
ess of whether the patient is in a clinical trial, and we take into
onsideration not mere numbers but several other factors before
e decide whether the patient is operable. In this series all patients
ere seen and evaluated by thoracic surgeons before performing
FA.
Dr Low. Just a comment before I go on to question 2, then. I
ould encourage you to solidify and make much more distinct the
riteria that you are using for medical inoperability in your article.
The second question concerns the patient selection section of
our article, which indicates that “most patients had PET scans.”
o you think that PET scans should routinely be a component of
he pretreatment assessment of these patients? Also, did all of these
atients undergo pretreatment CT-guided biopsies to confirm a
iagnosis before RFA therapy?
Dr Pennathur. Those are all excellent questions. This study
ent on over a period of 3½ years. Early on, PET scans were not
outinely approved by insurance companies, and subsequently they
ere approved. Yes, I think a PET scan should be a part of the
valuation of these patients routinely. In this series 80% of the
atients had a PET scan.
Regarding your second question, everybody had a CT-guided
iopsy, and some of them were performed by the surgeon himself
efore the RFA. The tissue diagnosis was confirmed to be NSCLC
n 18 of these patients, and in 1 patient it was called highly
uspicious. Clinically, this patient had a suspicious lesion that was t
The Journal of Thoracicighly PET active, and with a suspicious call, we went ahead with
FA, but everybody else had a clear documentation of NSCLC.
Dr Low. Your report states that 6 patients died, with a median
ollow-up of 13.5 months. How many of these deaths were cancer
elated?
Dr Pennathur. That is again a good question. We have not
ctually analyzed that as cancer specific versus noncancer specific.
everal of the patients did not die at the University of Pittsburgh,
nd on preliminary review and discussion with the primary phy-
ician, it appears that at least some of these were not cancer
elated, and we are in the process of ascertaining these data.
Dr Low. Your study demonstrates that pneumothoraces were
mmediate complications in 63% of your cases, although only 1
atient required a chest tube for greater than 4 days. Your main
ompetition for localized nonsurgical treatment for stage I lung
ancer is, of course, stereotactic radiation, which does not require
ny treatment-related intrathoracic instrumentation and can be
sed for more central tumors than those to which you have applied
FA in your series. Current reports of stereotactic radiation indi-
ate local control rates of up to 80% to 90% at 1 and 2 years.
pecifically, what do you see as the major advantages of RFA over
tereotactic radiation?
I would like to thank the association for the opportunity to
iscuss this article.
Dr Pennathur. Again, an excellent point. I think that SRS and
FA could be potentially used in the same group of patients and in
act can be used in a complementary fashion. We do not use RFA
or central lesions because of the proximity of the pulmonary
rtery and the bronchus, and therefore this is primarily applicable
or peripheral lung tumors. Stereotactic radiosurgery (SRS) can be
sed for central lung lesions, although at a decreased dose. In
erms of the analysis of the results of SRS, I have not found
nything in the United States with long-term follow-up. That is one
f the reasons we are studying SRS very closely. One of the few
ublications in the United States was by Dr Richard Whyte, a
ulticenter trial, and the other publication was from Dr Timmer-
an. He reported a total of 37 patients with stage I NSCLC,
noperable patients. Median follow-up was 14 months, and the
5-month overall survival was 65%; therefore I do not see the data
s mature enough to comment on SRS in the United States.
imilarly, we have also reported our initial experience with SRS
ith a median follow-up of 15 months. There are more data
vailable in Japan, but the experience in the United States, I think,
s still evolving. That is one of the things that we really want to
tudy. I think there might be a complementary role for SRS in
ombination with RFA.
Dr Harold Urschel (Dallas, Tex). Thank you, Dr Pennathur.
hat was a very nice presentation. How about making a comment
n the Cyberknife, the linear accelerator with the robot that actu-
lly treats the same kind of lesions, including now, hopefully,
entral lesions and comparing it with the possibility—we are in the
tanford, Pittsburgh, Dallas, Georgetown, and Boston group—of
rying to find these cases with what we think is a better approach.
hat do you think about that?
Dr Pennathur. Thank you for your comments. I think Cy-
erknife is one of the 3 available pieces of equipment by which we
an deliver SRS and is a frameless system. In the United States I
hink we have only a fair experience with stereotactic surgery. One
and Cardiovascular Surgery ● Volume 134, Number 4 863
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G
TSoint I want to mention that Dr Low alluded to earlier was the need
or thoracic procedures, which is also required for SRS; that is, you
ave to place fiducials to mark and track the tumor for SRS. When
lacing fiducials, you need typically about 3 to track the tumor. In
ur institution we place these fiducials with CT guidance, and we
o the treatment planning with radiation oncology before SRS
lso. The fiducials are not benign. We need to place the coaxial
eedle about 3 times or so in the lung and place the fiducials. I
annot remember the percentages, but there is a significant inci-
ence of pneumothorax with the placement of fiducials. For the
ore central lesions, we might be able to perform the fiducial
lacement with the bronchoscope in the future and that might
void some of the pneumothorax complications, but at the mo-
ent, we are doing percutaneous CT-guided fiducials, which do
ause pneumothoraces. I think in this area the multicenter trial we
ave with Dr Urschel, Dr Whyte, and Georgetown-Boston is going
o be very important in answering some of the questions in terms
f SRS, patient selection, and evaluation of long-term results.
nlike RFA, in which the complications you see are within the
rst month typically, with SRS, particularly for central lesions, you
ee complications, such as bronchial stenosis and so forth, months
nd sometimes more than a year later down the road because of the
ffects of radiation with fibrosis. Therefore I think more long-term
tudies are required for us to really define the role of which patient
ight be more suitable for SRS versus RFA and whether there is
complementary role to using both of them.
Dr Eric Vallieres (Seattle, Wash). I appreciated your study and
on’s and everyone else’s comments. I think in the future when
ou are going to compare these various modalities you are going p
64 The Journal of Thoracic and Cardiovascular Surgery ● Octoo have to include cost. Radiation tools are not free. I think you are
oing to have to include hospital stay and how many treatments
hey need. This is a 1-day treatment. If your patient does not have
ny complications, when do you send him home? What is your
ospitalization time on these?
Dr Pennathur. Thank you for your comments and questions.
he median hospital stay for us was 3 days. This patient group was
lderly, with multiple comorbidities, and we admitted almost all of
hem. There is usually a zone of inflammation after the RFA, and
ome have a pigtail catheter for the pneumothorax. Typically, we
dmit them for a couple of days or so and then send them home.
Dr Vallieres. I think all of these factors are going to have to
eigh in because you know most of these folks die of their
oncancer; that is, they have a noncancer death. They die of their
omorbidities, and therefore really what it is going to come down
o is cost and how quickly you can deliver the treatment and get
hem home.
Dr Pennathur. I think that is an excellent point. Costwise I
hink the Cyberknife and the SRS are quite expensive, and the
nstitution has to invest the money in that. When you place
ducials and if the patient has a pneumothorax, we admit them,
nd that requires a few days’ hospitalization; then the patient
omes back for the radiosurgery, which is usually done as an
utpatient. With SRS, however, typically it is only 3 days as
pposed to the 6 weeks of treatment that is required for conven-
ional radiation.
I thank the Association for the privilege of presenting this
aper.
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